Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000439746

Medchemexpress LLC Firmonertinib mesylate | 2130958-55-1 | 100.0% | 664.70 | 1 G
SDP

Catalog No. 5000439746
Encompass_Preferred

Firmonertinib mesylate is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. It effectively inhibits EGFR active mutations and the T790M acquired resistant mutation, making it a valuable compound for cancer research, particularly for advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.

  • Orally active
  • Mutant-selective
  • Blood-brain barrier penetrant EGFR inhibitor
  • Inhibits EGFR active mutations
  • Inhibits T790M acquired resistant mutation
  • Potential for cancer diseases research
  • Especially for advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation

Catalog No. 50-004-39746 Supplier Medchemexpress LLC Supplier No. HY112870A1G
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Firmonertinib mesylate is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. It effectively inhibits EGFR active mutations and the T790M acquired resistant mutation, making it a valuable compound for cancer research, particularly for advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.

  • Orally active
  • Mutant-selective
  • Blood-brain barrier penetrant EGFR inhibitor
  • Inhibits EGFR active mutations
  • Inhibits T790M acquired resistant mutation
  • Potential for cancer diseases research
  • Especially for advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.